GenBio AI Expands Global Leadership with Ziv Bar-Joseph as Co-Founder and Chief Scientific Officer
GenBio AI is proud to welcome Ziv Bar-Joseph as Co-Founder and Chief Scientific Officer. In this pivotal role, Bar-Joseph will spearhead efforts focusing on the integration and utilization of GenBio AI’s cutting-edge multiscale foundation models. His leadership is expected to make significant contributions to advancing drug discovery and revolutionizing medicine, among other areas. Through his visionary guidance, GenBio AI aims to redefine AI applications in biology and push the boundaries of biological research.
Bar-Joseph arrives at GenBio AI with a wealth of expertise from Sanofi, a renowned global pharmaceutical leader. During his tenure as Vice President and Head of R&D Data and Computational Sciences, he led multidisciplinary teams that harnessed the power of machine learning, computational biology, and data science to accelerate the discovery of drugs and vaccines. Alongside his industry experience, Bar-Joseph holds an esteemed academic position as the FORE Systems Professor of Computer Science at Carnegie Mellon University (CMU). His research delves into biological systems modeling and AI applications in genomics and systems biology, earning him accolades such as the 2012 Overton Prize in computational biology.
“GenBio AI is constructing a world-class research environment to pioneer the first AI-driven Digital Organism (AIDO), and I am thrilled to join this innovative team advancing AI-driven biology,” shared Ziv Bar-Joseph. “The unique ambition of GenBio AI to create such an avant-garde model aligns with my passion, and I am eager to lead the team towards groundbreaking discovery.”
Eric Xing, Co-Founder and Chief Scientist of GenBio AI, expressed his enthusiasm about Bar-Joseph’s appointment: “Ziv is a distinguished colleague from CMU, and his unparalleled expertise in computational biology and AI will be key to shaping the research and development trajectory of GenBio AI. We are ecstatic to have him with us as we aim to extend the frontiers of scientific discovery.”
GenBio AI is poised to introduce a new era in the realms of medicine and biotechnology. The company is leveraging integrated multiscale foundation models that provide a comprehensive view of the intricate biology that governs living cells, tissues, and organs. These pioneering models are set to revolutionize biological and biomedical discovery, paving the way for advancements ranging from fundamental research to translational medicine and drug discovery, ultimately enhancing human life.
Showcasing their groundbreaking work, the GenBio AI team presented six technical papers outlining their novel approach to constructing the world’s first AIDO at the prestigious 38th Annual Conference on Neural Information Processing Systems (NeurIPS), a leading conference in AI research.
With a global presence in Palo Alto, Abu Dhabi, and Paris, GenBio AI remains dedicated to transforming biological research. It is steadfast in building a platform tailored to model the complexity of biological systems across different scales, including molecules, cells, tissues, and phenotypes. This initiative represents a significant leap forward in our understanding and manipulation of biological complexity, promising to lead to innovations that can profoundly impact healthcare and the biological sciences.
